Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 201–300 of 1,014
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
“The primary endpoint was monotherapy failure and the patients were treated for a median of 4 years [39].”
BackgroundInfluentialSulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients
Monami, M., Cresci, B., Colombini, A., Pala, L., Balzi, D., Gori, F., Chiasserini, V., Marchionni, N., Rotella, C. M., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-1736 · Cited by 194
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 194
Self-citationmTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Ardestani, A., Lupse, B., Kido, Y., Leibowitz, G., & Maedler, K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.004 · Cited by 190
Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Combination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor
DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12982 · Cited by 192
Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., Lopez, D. S., van Veldhoven, K., Sacerdote, C., Ashby, D., Vineis, P., Tzoulaki, I., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0584 · Cited by 190
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
PPAR dual agonists: Are they opening Pandora's Box?
BALAKUMAR, P., ROSE, M., GANTI, S., KRISHAN, P., & SINGH, M. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.03.002 · Cited by 190
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Castagno, D., Baird-Gunning, J., Jhund, P. S., Biondi-Zoccai, G., MacDonald, M. R., Petrie, M. C., Gaita, F., & McMurray, J. J. V. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.030 · Cited by 190
Lorenzati, B., Zucco, C., Miglietta, S., Lamberti, F., & Bruno, G. (2010) · Pharmaceuticals · doi:10.3390/ph3093005 · Cited by 185
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
Gross, B., & Staels, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.004 · Cited by 186
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S. F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. A., et al. (2009) · Diabetes · doi:10.2337/db08-0896 · Cited by 184
Dagenais (2008) · doi:10.2337/dc07-1868 · Cited by 183
Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040156 · Cited by 182
“needed [3–4].”
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
“2% of initial weight in all studies) with metformin [19, 22], with the advantage that adding this hypoglycemic agent to insulin therapy may reduce its negative effect on weight [24-26] Acarbose causes a reduction in the intestinal absorption of glucose, thus inducing a reduction in the daily caloric intake, however, t…”
BackgroundBone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Lecka-Czernik, B. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0027-y · Cited by 183
The Impact of Type 2 Diabetes on Bone Fracture Healing
Marin, C., Luyten, F. P., Van der Schueren, B., Kerckhofs, G., & Vandamme, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00006 · Cited by 181
Zinman, B., Haffner, S. M., Herman, W. H., Holman, R. R., Lachin, J. M., Kravitz, B. G., Paul, G., Jones, N. P., Aftring, R. P., Viberti, G., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0572 · Cited by 180
Self-citationGómez-Banoy, N., Guseh, J. S., Li, G., Rubio-Navarro, A., Chen, T., Poirier, B., Putzel, G., Rosselot, C., Pabón, M. A., Camporez, J. P., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0610-4 · Cited by 178
Glycemic Management of Type 2 Diabetes Mellitus
Ismail-Beigi, F. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1013127 · Cited by 177
Secondary Failure of Metformin Monotherapy in Clinical Practice
Brown, J. B., Conner, C., & Nichols, G. A. (2010) · Diabetes Care · doi:10.2337/dc09-1749 · Cited by 178
The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0787 · Cited by 176
“Additional support for this interpretation comes from the apparently more-rapid progression of type 2 diabetes observed in youth in the TODAY study than in a similar study in adults treated with the same glucoselowering medications (2,3).”
ResultSelf-citationNannipieri, M., Mari, A., Anselmino, M., Baldi, S., Barsotti, E., Guarino, D., Camastra, S., Bellini, R., Berta, R. D., & Ferrannini, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0446 · Cited by 178
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 169
for the ADOPT Study Group and the RECORD Steering Committee, Home, P. D., Kahn, S. E., Jones, N. P., Noronha, D., Beck-Nielsen, H., & Viberti, G. (2010) · Diabetologia · doi:10.1007/s00125-010-1804-y · Cited by 177
Self-citationSGLT2 inhibitors in the treatment of type 2 diabetes
Hasan, F. M., Alsahli, M., & Gerich, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.014 · Cited by 173
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction
White, M. G., Shaw, J. A. M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc16-0619 · Cited by 174
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., & Philip, S. (2010) · Health Technology Assessment · doi:10.3310/hta14360 · Cited by 176
Kojima, T., Mizukami, K., Tomita, N., Arai, H., Ohrui, T., Eto, M., Takeya, Y., Isaka, Y., Rakugi, H., Sudo, N., et al. (2016) · Geriatrics & Gerontology International · doi:10.1111/ggi.12890 · Cited by 172
Opportunities and challenges in using real-world data for health care
Rudrapatna, V. A., & Butte, A. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129197 · Cited by 174
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka-Czernik, B. (2016) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 174
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
Monami, M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.015 · Cited by 174
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
Hirst, J. A., Farmer, A. J., Dyar, A., Lung, T. W. C., & Stevens, R. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2856-6 · Cited by 173
Metformin reverses the deleterious effects of high glucose on osteoblast function
Zhen, D., Chen, Y., & Tang, X. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.05.002 · Cited by 175
Dungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
“However, many immunomodulation therapies are used safely in autoimmune and rheupeutically for glucose lowering in T2D and for diabetes prevention (63, 64) and partition triglycerides out of the liver in patients with steatosis (65).”
Göke, B., Gallwitz, B., Eriksson, J., Hellqvist, Å., Gause-Nilsson, I., & for the D1680C00001 Investigators (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02510.x · Cited by 173
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Shah, A. S., Zeitler, P. S., Wong, J., Pena, A. S., Wicklow, B., Arslanian, S., Chang, N., Fu, J., Dabadghao, P., Pinhas‐Hamiel, O., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13409 · Cited by 170
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Home, P., Riddle, M., Cefalu, W. T., Bailey, C. J., Bretzel, R. G., del Prato, S., Leroith, D., Schernthaner, G., van Gaal, L., & Raz, I. (2014) · Diabetes Care · doi:10.2337/dc13-2743 · Cited by 167
Inflammatory mechanisms of diabetic complications
Williams, M. D., & Nadler, J. L. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0038-y · Cited by 170
Shockley, K. R., Lazarenko, O. P., Czernik, P. J., Rosen, C. J., Churchill, G. A., & Lecka‐Czernik, B. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21994 · Cited by 169
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0244 · Cited by 162
Self-citationUnraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Di Marzio, D. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s993 · Cited by 169
Sulfonylureas: A New Look at Old Therapy
Thulé, P. M., & Umpierrez, G. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0473-5 · Cited by 165
Higgins, L. S., & DePaoli, A. M. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28449e · Cited by 166
Glintborg, D., & Andersen, M. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903247873 · Cited by 159
Chalasani, N. P., Sanyal, A. J., Kowdley, K. V., Robuck, P. R., Hoofnagle, J., Kleiner, D. E., Ünalp, A., & Tonascia, J. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.09.003 · Cited by 168
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
Quinn, C. E., Hamilton, P. K., Lockhart, C. J., & McVeigh, G. E. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707452 · Cited by 166
Functional Assessment of Pancreatic β-Cell Area in Humans
Meier, J. J., Menge, B. A., Breuer, T. G. K., Müller, C. A., Tannapfel, A., Uhl, W., Schmidt, W. E., & Schrader, H. (2009) · Diabetes · doi:10.2337/db08-1611 · Cited by 163
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2006) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd002967.pub2 · Cited by 163
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 165
Tan, C. P., Feng, Y., Zhou, Y.-P., Eiermann, G. J., Petrov, A., Zhou, C., Lin, S., Salituro, G., Meinke, P., Mosley, R., et al. (2008) · Diabetes · doi:10.2337/db08-0130 · Cited by 163
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Mahaffey, K. W., Hafley, G., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J., Newby, L. K., Komajda, M., McMurray, J., Bigelow, R., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.004 · Cited by 163
“9%) appears consistent with CV outcomes reported in recent systematic reviews,(9) although the populations, study designs, follow-up, event definitions, and ascertainment varied.(10-27) A comparison of differences in the classification of cause of death and occurrence of the nonfatal end points between 2 experienced C…”
ResultHow safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 161
Self-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Osteoporosis among patients with type 1 and type 2 diabetes
Räkel, A., Sheehy, O., Rahme, E., & LeLorier, J. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.10.008 · Cited by 161
Ghosh-Swaby, O. R., Goodman, S. G., Leiter, L. A., Cheng, A., Connelly, K. A., Fitchett, D., Jüni, P., Farkouh, M. E., & Udell, J. A. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30038-3 · Cited by 159
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
Cholesterol in islet dysfunction and type 2 diabetes
Brunham, L. R., Kruit, J. K., Verchere, C. B., & Hayden, M. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33296 · Cited by 158
“treatment has been reported to increase the risk of myocardial infarction (21) and hip fractures (22).”
BackgroundGlycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?
Montori, V. M., & Fernández-Balsells, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00008 · Cited by 160
Colmers, I. N., Bowker, S. L., Majumdar, S. R., & Johnson, J. A. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.112102 · Cited by 157
Feng, Y., Mao, G., Ren, X., Xing, H., Tang, G., Li, Q., Li, X., Sun, L., Yang, J., Ma, W., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2248 · Cited by 156
Beta cell mass in diabetes: a realistic therapeutic target?
Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-0936-9 · Cited by 155
Insulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 153
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Habib, Z. A., Havstad, S. L., Wells, K., Divine, G., Pladevall, M., & Williams, L. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1385 · Cited by 153
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 154
Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus
Akash, M. S. H., Shen, Q., Rehman, K., & Chen, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23057 · Cited by 170
Mechanistic aspects of carotenoid health benefits – where are we now?
Bohn, T., Bonet, M. L., Borel, P., Keijer, J., Landrier, J., Milisav, I., Ribot, J., Riso, P., Winklhofer‐Roob, B. M., Sharoni, Y., et al. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422421000147 · Cited by 172
Personalized Management of Hyperglycemia in Type 2 Diabetes
Raz, I., Riddle, M. C., Rosenstock, J., Buse, J. B., Inzucchi, S. E., Home, P. D., Del Prato, S., Ferrannini, E., Chan, J. C. N., Leiter, L. A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0512 · Cited by 143
Mathieu, C., Ranetti, A. E., Li, D., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Hansen, L., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc15-0779 · Cited by 150
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09077 · Cited by 172
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
“This was clearly demonstrated in the ADOPT (diabetes outcome progression trial) study, in which monotherapy with rosiglitazone, metformin, and glibenclamide was examined over a 4-year study period: hypoglycemia occurred in approximately 10% of patients on rosiglitazone versus 12% of patients on metformin and more than…”
Fujita, Y., & Inagaki, N. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12214 · Cited by 148
Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 147
Gillett, M., Royle, P., Snaith, A., Scotland, G., Poobalan, A., Imamura, M., Black, C., Boroujerdi, M., Jick, S., Wyness, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16330 · Cited by 146
Filozof, C., & Gautier, J. ‐. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02938.x · Cited by 145
Arnold, J. M. O., Howlett, J. G., Dorian, P., Ducharme, A., Giannetti, N., Haddad, H. A., Heckman, G. A., Ignaszewski, A. P., Isaac, D., Jong, P., et al. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70211-8 · Cited by 167
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
Yamaguchi, T., Kanazawa, I., Yamamoto, M., Kurioka, S., Yamauchi, M., Yano, S., & Sugimoto, T. (2009) · Bone · doi:10.1016/j.bone.2009.05.003 · Cited by 147
Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 147
Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O’Keefe, J. H., Carter, M. D., & Lavie, C. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.8.741 · Cited by 173
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Rosenstock, J., Marx, N., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Bluhmki, E., Patel, S., Johansen, O.-E., & Woerle, H.-J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112475102 · Cited by 144
Self-citationTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 158
Retnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B., & Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-0893 · Cited by 136
Self-citationPeroxisome proliferator-activated receptors, Metabolic Syndrome and Cardiovascular Disease
Azhar, S. (2010) · Future Cardiology · doi:10.2217/fca.10.86 · Cited by 160
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 153
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 153
The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes
Hannon, T. S., & Arslanian, S. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12939 · Cited by 137
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.